Retatrutide + Cagrilintide Pen 35mg / 2.4ml

This combination pairs a triple GLP-1/GIP/glucagon agonist with an amylin analogue. The 2 classes act on separate satiety and energy-expenditure pathways; the amylin–GLP-1 pairing has shown additive weight effects in the CagriSema programme (Lancet 2021).

Designed for protocols where a single incretin analogue has reached a plateau and a second mechanism is warranted.

Presentation

• Format: Pre-filled injection pen
• Strength: 35mg / 2.4ml
• Storage: refrigerate at 2–8 °C; keep away from light

Supplied to healthcare professionals and their patients for use under medical supervision. Product information is educational and does not replace clinical judgement.